Start-up
A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living with HIV
Learn MoreStart-up
Development and validation of an anal cancer screening algorithm in HIV-positive men who have sex with men
Learn MoreEnrolling
A multicenter, randomized controlled trial of the efficacy, safety and immunogenicity of the 9-valent human papillomavirus (HPV) vaccination in preventing recurrence of high-grade anal dysplasia in HIV-positive men who have sex with men (MSM)
Learn MoreOngoing
A randomized controlled, open-label trial examining the efficacy, safety, and tolerability of ablative therapies for high-grade anal dysplasia versus observation alone in HIV-positive men who have sex with men (MSM) – part of HPV-SAVE study.
Learn MoreEnrolling
Development and validation of an anal cancer screening algorithm in HIV-positive men who have sex with men (MSM) – part of HPV-SAVE study.
Learn MoreOngoing
A study of an HPV VLP vaccine in a cohort of HIV positive girls and women
Learn MoreCompleted
A Phase II, prospective, open-label, pilot study of the tolerability, safety, and efficacy of Argon plasma coagulation for the treatment of anal intraepithelial neoplasia grade 2 or 3 in HIV-positive men having sex with men
Learn MoreReporting
A pilot study of a novel, mRNA-based assay for the diagnosis of anal HPV infection HIV-positive MSM
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
